Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

Offerings
About

Showing posts from November, 2025

Posts

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

on November 01, 2025

AbbVie Autoimmune Diseases Diabetes Mellitus, Insulin-Dependent Funding Immune Tolerance Regeneron Regulatory T-Lymphocytes sanofi Series A thymus-targeted therapy Tregs Zag Bio

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Expert Flags Potential 'Honeymoon Effect' as Rapport Heads Towards Phase III Epilepsy Trials

on November 01, 2025

Biological Markers drug-resistant focal seizures Epilepsy Honeymoon Effect KOL Bulletin mid-stage Phase 3 Clinical Trials RAP-219 Rapport Therapeutics Seizures

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Dyne Therapeutics' z-rostudirsen Shows Durable Efficacy, Supporting Positive Regulatory Outlook

on November 01, 2025

Accelerated Approved Biological Markers Clinical Trials DELIVER (veterinary product) Dyne Therapeutics Effectiveness Functional improvement Muscular Dystrophy, Duchenne regulatory approval z-rostudirsen

+

Get link
Facebook
X
Pinterest
Email
Other Apps

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

on November 01, 2025

ESMO Congress Event-Free Survival Immunotherapy KEYNOTE-671 Keytruda Non-Small Cell Lung Carcinoma Overall Survival pembrolizumab perioperative Standard of Care

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Otsuka Acquires Asia-Pacific Rights to 4D Molecular Therapeutics' Retinal Gene Therapy 4D-150 for $85 Million

on November 01, 2025

4D Molecular Therapeutics ' Asia-Pacific gene therapy Macular edema due to diabetes mellitus Ophthalmology specialty Otsuka strategic partnership wet age-related macular degeneration

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

on November 01, 2025

Biktarvy cell therapy sales financial results Gilead Sciences HIV franchise Livdelzi Q3 Tecartus Trodelvy Veklury Yescarta Yeztugo

+

Get link
Facebook
X
Pinterest
Email
Other Apps

BMS Battles Deeply Ingrained Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates

on November 01, 2025

Alzheimer 's disease Antipsychotic Agents Cobenfy Dopamine D2 Receptor Drug Kinetics drug market earnings Myers Squibb prescribing habits Psychotic Disorders Schizophrenia Trimonthly Uptake

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

November 20257
October 2025222
September 2025190
August 2025161
July 2025130
June 2025159
May 2025174
April 2025191
March 2025205
February 2025198

January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved gene therapy Obesity Vaccines Artificial Intelligence Investments Drug Industry Eli Lilly

Neoplasms Market layoffs Acquisition Glucagon-Like Peptide 1 Pfizer Transplant Registry Unified Management Program Policy manufacturing restructuring Pharma Roche (company) sanofi AstraZeneca Novartis Infrequent Autoimmune Diseases Cell Therapy Drug Development Drug Discovery COVID19 (disease) Inhibitor Nordisk drug price Safety Biopharma CHARGE Syndrome Industry United States Merck U.S. Biological Factors Leadership SmithKline Beecham expansion China CEO Prices Biotechnology Centers for Disease Control and Prevention (U.S.) Overall Survival Immunology Muscular Dystrophy, Duchenne Eli Myers Precision Medicine R&D RFK Jr. Sales - occupational activity Administration occupational activities Antibody-Drug Conjugates Wegovy biotech Alzheimer 's disease Phase 3 Staff public health medicine (field) Elevidys Partnership Phase 3 Clinical Trials Antibodies Regeneron milestone payments Dosage Forms Drug Approval Keytruda UK Changing Effectiveness Financial cost IPO Immunotherapy Oral cavity semaglutide squibb Amgen Collaboration Health care facility Phase 3 Trial Schizophrenia Zepbound innovation AbbVie Advisory Committees Biogen Cancer Therapeutic Procedure Funding Malignant neoplasm of breast NIH Mouse Progression-Free Survival Weight Loss Growth Moderna Solid Neoplasm trends qualifier Biological Markers Non-Small Cell Lung Carcinoma Weight-Loss Agents therapeutic autologous dendritic cells Appointments Biological Science Disciplines Clinical Research Failure (biologic function) Malignant neoplasm of lung Study on Hold clinical trial failure competition ACIP Bayer BioNTech Biosimilars Multiple Myeloma PDUFA Phase 2 trial Robert F. Kennedy Senate concerns genentech production rejection 2025 Accelerated Diabetes Evaluation Gene Modification HHS Medicare Phase 2 Clinical Trials Series Takeda Trump administration pipeline regulatory Biosciences Bispecific CAR-T Medicaid Programs - Publication Format RNA Response process TNFRSF19 gene clinical development dosing earnings federal pharmaceutical manufacturing pharmaceutical tariffs supply chain Antibodies, Bispecific Capital Cardiovascular Diseases Clustered Regularly Interspaced Short Palindromic Repeats Confirmation Gilead Sciences Legal patent Leqembi MASH government leadership change tariffs venture Adverse event Bio Cancer Research Complete Deferred Discontinuation (procedure) Duchenne EU Efficiency Eisai Flagship Health Policy J&J LB-102 Muscular Dystrophy Myasthenia Gravis Nasdaq Pricing Robert F. Kennedy Jr. cellular targeting cost-cutting development aspects licensing agreement research strategic alternatives Agonist Amyotrophic Lateral Sclerosis Automation Child Colorectal Carcinoma Epilepsy Facility (object) Financial savings Gilead HIV prevention Johnson & Johnson Johnson and Johnson M&A Manufacture Mediation Medical Devices Metabolic Diseases Metsera Mounjaro Neuroscience discipline North Carolina Parkinson 's disease Phase III Surgical construction alpha 1-antitrypsin direct-to-consumer drug safety patient deaths submission venture capital ASCO Antipsychotic Agents Astellas Benefit Biotech Layoffs Budgets CBER Chronic disease Clinical Data Combined Diabetes Mellitus, Non-Insulin-Dependent Elderly (population group) Endpoints Malignant Neoplasms Malignant neoplasm of urinary bladder Nation Ophthalmology specialty Ozempic Pauses Pharmacotherapy Phase 3 trials Placebos Prasad Preventive monitoring Pulmonary arterial hypertension RNA Interference Recommendation Respiratory syncytial virus Rheumatoid Arthritis Sectioning technique Shakeup Technology acute biotech industry drugmakers executive order in vivo melanoma orforglipron royalties safety profile Access BARDA Board of Directors CDER CDMO Cautionary Warning Cells Contract agreement Daiichi Dosage Dupixent Health Homo sapiens Hypertensive disease Idiopathic Pulmonary Fibrosis Kidney Diseases Lenacapavir Liver diseases Makary Metastatic castration-resistant prostate cancer Nance-Horan syndrome PD-L1 PREP gene Patient Death Pharmaceutical Services Response Letter Sankyo Series B financing Transition Mutation VK2735 biobucks cardiometabolic diseases cash runway diagnostics immuno-oncology merger optimization regulatory approval strategic Agencies BTK inhibitor Breakthrough Therapy CAR-T therapy COPD Cystic Fibrosis Dermatitis, Atopic Disease Outbreaks ESMO Enhertu European (ethnic group) Exelixis Exit Extension Frequency of Responses GLP-1 receptor Generalized Heather Flick Melanson Identifier Illumina Immunotherapy for cancer Impact food supplement Indirect Infant Labels (device) Leukemia Leukemia, Myelocytic, Acute Malignant neoplasm of prostate Merck KGaA Monoclonal Antibodies Mutation National Security Neurodegenerative Disorders Novo Nordisk PAH Pioneering RNA Editing Rare Diseases SMPX gene Secretary Series B funding Severe (severity modifier) Small cell carcinoma of lung Spinal Muscular Atrophy SpringWorks Toxicity aspects Translucent Trump tariffs Vaccine Safety aspects of adverse effects asset biotech partnerships corporate delays digital health launch pembrolizumab private equity shipment subcutaneous 3-Methylglutaconic aciduria type 2 AAVS1 gene ATTR-CM Acquisition (action) Advice Alopecia Antineoplastic Agents Application procedure Autistic Disorder Autoimmune Bankruptcy Biomechanical compliance Blenrep Boehringer Boehringer Ingelheim Bourla Buckham Burning Mouth Syndrome CHMP Cancer Vaccines Cancer of Neck Combined Modality Therapy Commission Contraceptives, Oral DOGE Decision Department of Health and Dependovirus Discover Drops - Drug Form Elamipretide Epidermal Growth Factor Receptor File (record) Gardasil Generative AI Generic Drugs Genomics Gomekli Hannah Anderson Head Immunization India Inflammation Japan LDL Cholesterol Lipoproteins Licensing Licensing Deal Liver Failure, Acute Long-term Maintenance Malignant neoplasm of stomach Maziar Mike Doustdar Myelocytic NVIDIA Novavax Opioids PCSK9 inhibitor Partner in relationship Platform Post-Traumatic Stress Disorder Priority Review Progressive Proteinuria Pulmonary Fibrosis Q3 R-Series RFK gene RNA, Small Interfering Radiopharmaceuticals Research Projects Rocket Science Score Seizures Statistical Significance Study models T-Lymphocyte T-cell engager TMEM79 gene Tagrisso Viking Weight maintenance regimen Worker chain disruption drug review early-stage factor IX financial results first human oral SERD partnerships pharmaceutical innovation public entity public health policy royalty settlement summit tirzepatide treatment-resistant depression upfront payment 2023 ADC Adult Affordability Akeso Alcon Alexion Anemia Antibody-Drug Anticoagulants BNT327 Big Pharma BioMarin Biologics License Application Biotherapeutics Blood - brain barrier anatomy Bovichtus CDC CNS disorder California Cardiovascular system Carlyle Chronic Kidney Diseases Chronic Spontaneous Urticaria Clinical Conditional Congress (U.S. Legislature) Contraceptives DKK1 gene DMD Disorder of eye Diversity Drug Prescriptions Drugs, Orphan Effect Episodic Europe Event-Free Survival Eylea Failed Family Turdidae (organism) FibroGen GLP-1/GIP dual agonist GZMH gene Galapagos Gene Silencing Glycogen storage disease type II Halozyme Hearings Heart Diseases Hot flushes IGA Glomerulonephritis IPOs IRA Import Inflammatory Bowel Diseases Injectables Insmed Insulin Ivonescimab Journavx Jr. K-ras Oncogene LDL-C LillyDirect Lundbeck Lung diseases Lupus Vulgaris Lynkuet MAHA MYELODYSPLASTIC SYNDROME Macular edema due to diabetes mellitus Malignant neoplasm of kidney Manufacturing Facilities Menopause Merck & Co. Misinformation Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Sclerosis Muscular Dystrophies, Limb-Girdle Narcolepsy Nerve Degeneration New Drug Application News [Publication Type] Opdivo Oral Otsuka PDCD1 gene Pediatric brand name Peter Marks PhRMA Phase 1 (qualifier value) Phase 2 Plant seeds Pliant Praxis Precision Medicines Presenile dementia Product containing glucagon-like peptide 1 receptor agonist (product) Q2 2025 RETINITIS PIGMENTOSA 1 RNA therapeutics Regenerative Medicine Regulatory Setback Replimune Rinvoq Risk Roivant Series D financing Small Interfering Small Molecule Stealth BioTherapeutics Stock Decline Surveys Suspensions TIGIT gene TYK2 gene Target Tecentriq Telemedicine Triglycerides Vascular Endothelial Growth Factor A Vinay Winrevair Withdraw (activity) Workforce Reduction acquisitions agonists alpha 1-Antitrypsin Deficiency authorization biology (field) biomanufacturing biotech collaboration biotech sector biotech startups chief of chikungunya vaccine chronic commercialization conditions court drug market eli lilly generics inhibitors manager manufacturing issues measles medtech mental health oncology pipeline onshoring perioperative pharmaceutical marketing pharmaceutical supply chain portfolio proposal - intent protein degrader regulatory submission regulatory uncertainty reorganization revenue growth skipping stocks strategic review trials upadacitinib zanzalintinib 2026 ADCs AI drug discovery AI-designed drug AI-driven Acelyrin Acute onset pain Adolescent (age group) Advanced phase Age related macular degeneration Albert Alkermes Alnylam Alumis Amlitelimab AnaptysBio Androgenetic Alopecia Angioedemas, Hereditary Apellis Apolipoprotein E4 Ascletis Asthma Ataxia Atrial Fibrillation Autoimmune thrombocytopenia Avidity Biosciences Awareness B-Lymphocytes BEACON-IPF Bavarian Nordic Bhattacharya Billion Black Populations Blindness BlueRock Therapeutics Brazil BridgeBio CD19 Antigens CD3 Antigens CRDMO CagriSema Cambridge Canada Capsid Cardiomyopathies Cash Cervical Atlas Cessation of life Chronic Lymphocytic Leukemia Chronic pain Clinical Nurse Specialists Clinical Trial Design Co. Cobenfy Complete Response Letter Concentra Biosciences Congenital CordenPharma CureVac Cystic Fibrosis Transmembrane Conductance Regulator DNA DNA Integration Datopotamab deruxtecan Datroway Detection Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diffuse Large B-Cell Lymphoma Ditiocarb Does speak Drug Delivery Systems Drug Shortage Durham Dyslipidemias ESR1 gene Eczema Emma Walmsley Endometriosis Enflonsia Event Expectations Eylea HD Familial chylomicronemia syndrome Forbion Freezing G-Protein-Coupled Receptors GLP-1s Genmab Genome Glycogen Storage Disease Type IIb Guanosine Monophosphate HER2-negative HHS layoffs HIV Halda Therapeutics Healthy Heart failure Hematologic Neoplasms Hims & Hers Holly Springs Hyperphagia Hypertriglyceridemia IL33 protein, human Imdelltra Immunostimulating conjugate (antigen) Impaired Improvement Increase Indication of (contextual qualifier) Indonesian language Ingelheim Injury of liver Intellia Interferes with Ionis Pharmaceuticals Ira (eukaryote) Janus kinase Jazz Jeffrey Kirin Kisunla Kymera Kyowa Laboratory Laboratory test finding Legal Legos License Litigation Liver Failure Logistics Lupus Erythematosus Lupus Erythematosus, Systemic MET-097i MFN Machine Learning Malaria MapLight Therapeutics Marty Menin Inhibitor Mental Depression Merus Midline (qualifier value) Migraine Disorders Mortality Vital Statistics Most-Favored-Nation Myasthenic Syndromes Myasthenic Syndromes, Congenital Myeloid Leukemia, Chronic Myers Squibb Myopia Narcolepsy type 1 Neurology speciality Neuromuscular Diseases Neuropsychiatry Neurosecretory Systems New New Jersey Non-Insulin-Dependent Novavax 's Ogsiveo OpenAI PARP1 gene PD-1/VEGF PD-1xVEGF Pain management Pancreatic carcinoma Parity Peptides Performance Pharma Industry Pharmaceutical merger Pharmacovigilance Phase 1 trial Phase 2 clinical trial Phase 3 clinical trial Pipeline Development Pounds Prader-Willi Syndrome Pressure- physical agent Privacy Prothena Psoriasis Psychotic Disorders Public Offering Quality R&D pipeline REMS RIPTAC RMAT RNA, Messenger Reaction Recursion RegenXBio Regulation Regulatory Action Regulatory Affairs Remote Research Personnel Respiratory physiology Restrictions Retinal Diseases Retirement Review [Publication Type] Revolution Medicines Robotics Rybrevant SPAC Scholar Rock Science of Chemistry Secretary Nomination Seqirus Series A Series B Series D Servier Spikevax SpinCo ' Spinocerebellar Stabilizer - function Subcutaneous Injections Subgroup A Nepoviruses Supernus Pharmaceuticals Systemic Systemic Scleroderma TREM2 Thermo Fisher Transection (procedure) Transitory Triple Negative Breast Neoplasms Trodelvy TrumpRx Unable to walk (finding) Uncertainty United States National Institutes of Health Urinary tract infection UroGen VG-3927 VRBPAC VX-264 Vabysmo Vaccination Vepdegestrant ViiV Healthcare Viking Therapeutics Viral Vector Vision Wave Life Sciences White House WuXi WuXi AppTec Yeztugo Zolgensma Zurzuvae adaptation analysts assets atezolizumab bemdaneprocel benzamide antipsychotic benzamide class bexotegrast biotech acquisition biotech merger bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine branded drugs cancer drugs capabilities childhood vaccine schedule clinical endpoints collaboration termination constraints data integration deal dealmaking decline departure - ActRelationshipType deramiocel deruxtecan direct-to-consumer sales domestic manufacturing drug efficacy drug manufacturing drug shortages engagers exon federal funding federal judge financing characteristics focal onset seizures giredestrant headquarters iTeos interleukin-6 language models mRNA Vaccine mimetics molecular glue monthly muscle-invasive bladder cancer nerandomilast nivolumab obinutuzumab operating profit ounce ovarian neoplasm oveporexton pacibekitug pandemic preparedness payers payment pharmaceutical acquisition pharmaceutical companies pharmaceutical sales pilot program pipeline reduction platforms precision oncology preclinical data psychedelic therapy regulatory compliance regulatory guidance roxadustat sNDA shareholder skepticism statutory scheme strategic collaboration strategic partnerships succession surge survival targets tariff terminations tolerability trastuzumab twice-yearly injection user fees vedotin 130-nm albumin-bound paclitaxel 15% 75% 8 AACR AACR25 ACR gene AERIFY-1 AERIFY-2 AH 001 AI-enabled ANGPTL3 AOC ASC30 ATG-201 Abeona Acadia Acute lymphocytic leukemia Adaptimmune Administration of prophylactic statin Administrative action Adoption AdvanCell Adverse effects Advocacy Age Agios Alameda Headquarters Alternative Altimmune Alzheimer 's Amvuttra Amylin AnHorn Medicines Analgesics Antagonist muscle action Antengene Antibiotics Antibody Therapy Antisense Oligonucleotides Anxiety Disorders Appia Bio Apply Arcus Arcus Biosciences Arenaria <Aves> Argenx Arrowhead Arvinas Atopic Audit Committee Australia AutoInjector Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Automobiles Availability of AviadoBio Ayrmid B-cell depletion BCG-Unresponsive BGM0504 BMS BNC210 BRUIN Bain Capital Beak Beijing Beyfortus Big Beautiful Bill Biktarvy Bill Anderson Bill Cassidy BioNTech 's BioNeMo Biochemical Pathway Biomedical Research Biopharma layoffs Bioscience Biotech Innovation Blackfoot language Bluebird Bio Body mass index procedure Boston Scientific Brain Neoplasms BrightGene Brinsupri Bronchiectasis Bruton 's tyrosine kinase inhibitor CD19xCD3 CD276 gene CDK2 protein, human CDK4/6 inhibitor CGM CLN-978 CNPV COMP360 COVID-19 Vaccines CRLs CSU CTSC gene CUTX-101 Capacity Capillary Leak Syndrome Capital Management Capital Partners Caplyta Capricor Therapeutics Carcinoma breast stage IV Cardiology discipline Cartesian Carvykti Cash Crunch Cataplexy Cavazzoni Celltrion Cerebral Edema Challenge Charles Chickenpox Chief Chief Legal Officer Chikungunya Fever China-based Chinese Language Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chugai City of Boston Clinical Failure Clinical Oncology Clinical Services Clinical Trial Failures Clinical action Closed Columvi Community Company Split Compass Pathways Complicated Compound Compounders Construction worker Consultation Consumer Safety Continuous glucose monitoring Contract Research Organization Conventional (Clear Cell) Renal Cell Carcinoma Corcept Corporate governance Cosentyx Country Covid vaccine Crackdown Creative Biolabs Cullinan Customer Cutaneous Cylembio Cytokinetics DB-OTO DEI DEL-AI DOJ Data Analysis Data Safety Daytime Somnolence Deafness Deal Value Deep Apple Degrader Delaware Denali Depletion Depression Depression, Bipolar Depression, Postpartum Dermatitis Dermatology field Diagnosis Diagnostic Imaging Disease Progression Disease-Free Survival Donald Trump Dordaviprone Dr. Droughts Drug Formulation Process Drug Regulations DualityBio Dystrophin EGFR-mutated ELAVL2 gene ENTR-601 ER-positive ESMO Congress Ebvallo Ecosystem Electrophysiology (science) Eligibility Determination Elivaldogene autotemcel Elon Employee Employment Termination Endo Engaged to be married Entrada Environment Enzymes Epigenomics Escherichia coli Evaluation procedure Evidence Excessive (qualifier value) Eye FCGRT gene FDA-approved FIBRONEER-ILD FLAURA2 trial FY2025 Fabhalta False Claims Act Farxiga Fast Track FcRn Federal Circuit Fertility Agents Fertilization in Vitro Fibromyalgia Fibrous histiocytoma of tendon sheath Fierce Financial Forecast Revision First line treatment Flatulence Focal Force Fortress Forzinity Foster City Fragile X Syndrome France Fraud Friedreich 's ataxia Fujifilm Functional Fund Raising Funds GABA Modulators GEP-NETs GLP-1/GIP GLP-1/GIP receptor agonist Gaithersburg Gastric Inhibitory Polypeptide Gazyva Gemini of Coiled Bodies Gender Gene Mutation Generic Competition Genrix Bio Geographic Atrophy George Tidmarsh Glaucoma Glycosylated hemoglobin A Goldcrest Goldman Sachs Govorestat Grail Guidelines HBr HELP Committee HLD-0915 HRS-5346 Hallopeau-Siemens Disease Health Care Market Health agencies Heart Hemoglobin A1c measurement Hengrui Pharma Hengrui Pharmaceuticals Hepatitis B Hereditary Diseases Herpes zoster disease Hetlioz Hidradenitis Suppurativa High High-Throughput Nucleotide Sequencing Hillhouse Investment Management Hims Holdings Home environment Hospitalization House mice Huntington 's disease Hyderabad Hypercholesterolemia Hyperlipidemia Hypertrophic obstructive cardiomyopathy Hypoparathyroidism ITM-11 IZERVAY Iambic Therapeutics Imaavy Imfinzi Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immunogenicity (package insert) Immunology pipeline Immunoregulation Immunovant Increased Incretins Incyte Individual Adjustment Infantile Neuroaxonal Dystrophy Infantile Severe Myoclonic Epilepsy Inflation Inflation Reduction Act Influenza Influenza virus vaccine Infusion procedures Inhibrx Innovent Biologics Inosine Triphosphate Insitro Insurance Intact Intellectual Property Interleukin-17 Interval Intra-Cellular Therapies Invasive Invasive meningococcal disease Inventiva Investor Reaction Io satellite Isomorphous Ixchiq J&J 's Jay Jay Bhattacharya Jaypirca Jorna Judge KGaA KOMET-001 KRP KRP-M223 Kailera Kennedy King Kyorin LAVA LEAP LGBTQ+ Lars Fruergaard Jørgensen Late stage Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Lecanemab Letter [Publication Type] Lila Sciences Lilly Gateway Labs Litifilimab Liver Long Intergenic Non-Protein Coding RNA Lonza Lp(a ) Luke Miels Lupus Nephritis Lymphoma MAGNITUDE trial MASP-3 Inhibitor MC4R protein, human MEK MET-233i MPLT MRGPRX2 gene MRT-6160 MSTAR MYOTONIC DYSTROPHY 1 Mabwell Madrigal Pharmaceuticals Mallinckrodt MariTide Massachusetts (geographic location) Measures MedKey Medical Research activity Medical Specialities Mehmet Meningococcal vaccine Menkes disease Mental deterioration Mesenchymal Stem Cells Metabolic Metabolic Syndrome X Mexico Microbicides Microbiome Microglia ModeX Molecular Glue Degrader Monte Rosa Therapeutics Monthly (qualifier value) Mozafancogene Autotemcel Mucopolysaccharidosis II Muscular Dystrophy, Facioscapulohumeral Musk secretion from Musk Deer Myasthenia Gravis, Generalized NBD1 NIH NPM1 Nasopharyngeal carcinoma Neuphoria Neurodevelopmental Disorders Neurofibromatosis 1 NewAmsterdam Pharma Newleos Nitroglycerin/Sodium Citrate/Ethanol Solution Non-Muscle Invasive Bladder Neoplasms Note (document) Novo Nucala Nurix ODAC OPKO Health Obesity Drug ObesityWeek 2025 Obicetrapib Obstetric Delivery Ocular Toxicity Odyssey Olezarsen OliX Oligonucleotides Omeros Opdualag Optogenetics Organoids Orphan Drug Designation PANSS PD-L1xVEGF PTC518 Padcev Papzimeos Parkinson Disease Patient access Paul Offit Pediatric Disorder Penmenvy Pennsylvania Pericardial effusion Personalized cancer care Petosemtamab Pharmaceutical Research Pharmacy facility Phase 1b Phase 2 trials Phase 2b Phase I Clinical Trials Phase II B Trial Philadelphia Phobia, Social Pipeline Progress Pivot Device Plexiform Poolbeg Postpartum Precigen Precision - temporal Precision immunology Preclinical Prediabetes syndrome Predictive analytics Pregnant Women Primary Biliary Cholangitis Primary Prevention Primary amyloidosis Project Project NextGen Projections and Predictions Protac Protein Degradation Protein Degradation, Metabolic Protein-tyrosine kinase inhibitor Proteins Proteomics Prussia Psilocybin Psychological inhibition Pulmonary Q1 2025 RAP-219 RECONNECT RGX-121 RP-A501 RSV Radiant heater Rapport Therapeutics Recruitment Recurrent respiratory papillomatosis Relapsing course Relocation of home or business Reparative closure Repatha Republican Respiration Disorders Response Letters Retinitis Pigmentosa Rett Syndrome Revenue Upgrade Reversal Rexulti Rilzabrutinib Rising River Laboratories Rocatinlimab Romvimza Rosnilimab SG&A SOPHiA GENETICS SPN-820 STARGLO STELLAR-303 Salts Samsung Sandoz Sarcoidosis Schrödinger Scientific Advisory Board Screening for cancer Self Confidence Senate Finance Committee Senate hearing Sense of identity (observable entity) Sentiment Septerna Sernova Services Sharing (Social Behavior) Shingrix Sibeprenlimab Sionna Site SkySTAR platform Skyhawk Skysona Sleep Social Welfare Social stigmata Sodium Channel Blockers Sofinnova Soleno Sotyktu Spinraza St. Louis Standard of Care Stelara Stem Cell Therapy Steroids Stock Crash Stock Surge Stock exchange Subcutaneous Keytruda Substance Use Disorders Super Bowl ad Surgical aspects Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Suzetrigine Svalbard Symbravo Syringes TAR 200 TCE TERN-601 TERN-701 TPTE2 gene Taiho Talzenna Tecartus Tecelra Tension Terns Teva Texas Thermo Fisher Scientific Tolebrutinib Transaction Treeline Trump Trump loyalists Truqap Tryngolza TuneLab Twice a day U.S.-China UGX-202 US US tariffs USPSTF Ulcerative Colitis Uncontrolled Union United States Health Resources and Services Administration United Therapeutics UnitedHealth Group Universities Unsolicited Adverse Event VANQUISH-1 VERVE-102 Vaccines, Combined Valneva Vanda Pharmaceuticals Vaxart Verona Vigil Vimkunya Vyne Vyvgart WVE-006 Wages Walmart Pharmacy Wayrilz Woman Workers World Health Organization Wugen Xtandi Yescarta Ypsomed ZEVASKYN Zaltenibart Zenas BioPharma Ziftomenib Zorevunersen acute pain treatment addiction advanced therapies agentic AI alfa alixorexton all-stock alpha therapies amisulpride anti-seizure medication anti-tumor activity antibody libraries apitegromab appeal approvals at-risk baxdrostat belrestotug benzamide biopharmaceutical development biopharmaceutical industry biopharmaceutical manufacturing biotech closures biotech downturn biotech partnership biotech startup biotechs black box boxed brensocatib brexpiprazole business development cabozantinib campus cancellation cancer care cancer pipeline carbetocin cardiometabolic cardiometabolic health cardiovascular pipeline care activity cell line development cell renal cell carcinoma charge amounts checkpoint inhibitor checkpoint inhibitors cholesterol chronic hand eczema cibotercept clinical pipeline clinical program commercial contract manufacturing cost-cutting measures danuglipron data privacy day deadline decentralized departures deucravacitinib dexamethasone digital transformation digital twins direct-to-patient discount disruption divestment domestic drug manufacturing domestic partnerships domvanalimab drug applications drug development halt drug launches drug rejection durability economic impact enforcement enzalutamide erbB-2 Receptor executive leadership expert federated learning fentanyl crisis fibroblast growth factor 21 fill-finish financial performance firings first-in-human first-line therapy generative AI generic pharmaceuticals governance growth outlook hair regrowth health disparity healthcare technology heart health high-risk high-risk groups human antibody hydrocortisone ianalumab import alert injunction investor itepekimab jet lag disorder lawsuit leadership shakeup leases lexicon liver transaminase losses mCRPC mRNA Vaccines mRNA therapies manufacturers mass layoffs meeting meloxicam mirdametinib mitomycin molecular glue degraders multispecific antibodies namilumab negotiation nervous system disorder neurological diseases next-generation non-opioid pain drugs nrSPMS older once-daily operational oral drug oral semaglutide oral therapies oral therapy oral treatment orexins outcomes patent cliff patent settlement patient safety payments pegcetacoplan pegozafermin personalized cancer pharma partnerships pharmaceutical competition pharmaceutical litigation pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline pivot pirfenidone placebo-controlled trials platform technology designation portfolio strategy preclinical programs primary endpoint probationary workers profit guidance protein degraders public trust radiopharma rates real-world data recipients reconciliation regorafenib regulatory environment regulatory filings regulatory review regulatory science regulatory strategy remibrutinib removal technique repeal research funding reshoring reshuffle resignation resilience resubmission risk mitigation risk-benefit analysis rizatriptan scalability seconds sertraline shareholders small molecule therapeutics solbinsiran specialty medicines spending startup startups stock drop stop work strategic brands strategic realignment strategic restructuring strategic shift sustainability synergies targeted therapies tariff exemption tenosynovial thimerosal threat tourmaline treprostinil palmitil inhalation powder tumor-activated user fee ustekinumab vaccine access valproic acid glucuronide value-based care vasomotor symptom vatiquinone velinotamig venetoclax vera virtual care vormatrigine women 's health xRNA zimislecel (3beta * * Global Expansion * * 10 mg 1964 200 2024 30% 340B 4D Molecular Therapeutics ' 50–59 55% 5alpha)-isomer 7.5 mg 90% 95% AACR-NCI-EORTC AAV antibodies AAV-based gene therapy AAVrh74 AAVrh74 vector AB-2100 AB001 ABI-5366 ABPI ABS-0871 ABS-1230 ABTECT-1 ABTECT-2 ACHIEVE-1 ACP-101 ACR-2316 ACUA AChR-Ab AD109 ADA25 ADAMTS-5 ADAPT-PD study ADARx AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AHA AI Factories AI agents AI drug design AI drug development AI guardrails AI humanoid robots AI models AI safety AI supercomputer AI tool AI ultrasound AI-designed AI-generated AI-powered diagnostics AI-powered healthcare AI/ML-enabled product AIR-001 AK006 AKAP9 protein AKAP9 protein, human AL ALK gene ALPHA3 trial ALS ALT-positive ALTO-203 ALZ-801 AMD AMG AML AMPA receptor modulator AMPA-PAM AMT-130 AMX0035 ANDA ANX005 AP01 AP02 AP3 APIs APJ ARCT-032 ARIA ARIA-E ARID1A mutation ARO-C3 ARO-SNCA ARROS-1 trial ARTBIO ASCEND trial ASCENT ASCO preview ASCO-GU ASCO25 ASCVD ASGCT ASPR ASTX029 ATI ATSN-101 ATSN-201 ATTAIN-2 ATX01 AURN001 AXS-14 AZD0780 Abata AbbVie CEO Abbas Kazimi Abbreviated New Drug Application Abe Bassan Abecma Abeona 's Abetalipoproteinemia Abivax Abnormality of mitochondrial metabolism Academia (organization) Academy of Pediatrics Acceleration Accord BioPharma Accurate (qualifier) Accuray Achieve Life Sciences Acne Vulgaris Acoramidis Acrivon Actinium Actio Actithera Active Activin E :* * Actuate Acute leukemia Adaptive Biotechnologies Adcetris Addictive Behavior Adenosine deaminase deficiency Adenovirus Infections Adherence To Medication Regime Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Adjuvant Therapy Adolescence Advanced Imaging Suite Advanced Manufacturing Technology Advanced Melanoma Adverse reaction to drug Adverum Biotechnologies Advisory Panel Aerska Afami-cel Afimetoran Africa Aggressive Aggressive Periodontitis Ahmed ElNawawi AiTEM AimedBio Airna Ajax Health Akeega Akeso 's Alarm device Albert Bourla Alchemab Alcohol Use Disorder Alcohol abuse Alcohol or Other Drugs use Aldeyra Aldose Reductase Inhibitor Alector Alexander Disease Algen Biotechnologies AlgoTx Allakos Allo-Glue platform Allogene Allogeneic Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia AlphaDirect technology AlphaFold AlphaMedix Alphabet Altanine Alteogen Altman Altuviiio Alyftrek Alzheimer Alzheimer 's disease psychosis Alzheimer 's psychosis Amazona Ambulatory Care Facilities American Depositary Receipts Americas AmericasMedicines.com Amezosvatein Amgen 's Amolyt Amphastar Amplify trial Amsterdam facility Amylin Analog Amylin Candidate Amyloid-targeting therapy Amyloidosis Amylyx Anabolism Analgesics, Non-Narcotic Analog Anatol Andembry Andreas Goutopoulos Andrew Grethlein Andrew Witty Andy Thomas Ang2 Angelini Pharma Animal Testing Animal Welfare Anktiva Ankylosing spondylitis Anne Anne Wojcicki Annexon Anniko Anomaly Ventures Ansa Biotechnologies Anselamimab Antares Anthos Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD52 Monoclonal Antibody ALLO-647 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Inflammatory Agents Antibiotic Resistance Antibiotic therapy Antistreptolysin O Anything Anzupgo Apis (invertebrate) Apnimed Apolipoproteins B Apollo robot Appeals court decision Apple Watch Apptronik Apretude Araris Arbitrating Arbuckle Arbutus Arch of foot Architecture Arcturus Arcturus Therapeutics ' Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Arrowhead Pharmaceuticals ArsenalBio Arteriosclerosis Arthritis Artificial (qualifier value) Artificial cardiac pacemaker Asarina Ascenta Capital Asia-Pacific Asian Americans Asian Indian Assembly (construction) Astellas Pharma Astex AstraZeneca 's Astria Atai Life Sciences Atara Atara 's Atara Biotherapeutics Atsena Attention Attenuated by (contextual qualifier) Attitude Attruby Autoantibodies Autoimmune Chronic Hepatitis Autonomous Research Avadel Pharmaceuticals Avalyn Avastin Avenzo Average Aves Avidity Awards Axial Axplora Axsome Axsome Therapeutics' Ayvakit Azafaros B cell immunomodulator program B-cell Select ™ technology BAFF‑R BAG3-associated BATNA BBI-355 BBI-825 BCG Vaccine BCL6 gene BCR BDTX-4933 BIOSECURE BL-B01D1 - 303 BMS-986322 BNT211 BPL BRCA BRENTUXIMAB BROADWAY BROADWAY trial BTKi BTN3A BX211 Bacterial Infections Baker Bambusa Therapeutics Bangalore plant Barinthus Basketball game Batoclimab Bausch Health Bay Area Beat Behavior Belén Belén Garijo Beqvez Bettis Bharat BiLockCatcher Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Big Data Big Pharma investors Bilirubin Billion Collaboration Bimzelx Bio-Informatics Bio-Rad Bio-Thera BioAge BioArctic BioAtla BioCapital BioCity BioClec BioCryst BioSpace Biochemistry Biocodex Bioeconomy Bioepis Biohaven Biological Assay Biomanufacturing Strategy Biomedicine Biomedicines Biopharm Biopharma regulatory issues Biopharma trade war Biosafety Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech pipeline shift Biotechnology Advantage Bivamelagon Blackstone Life Sciences Blackwell Ultra GPU Blepharitis Blood Blood Coagulation Disorders Blueprint Medicines Blujepa Board Resignation Board appointment Board change Bobby Hunter Body Composition Boltz-1 Boost Boston Pharmaceuticals Boston event Boundless Brain Brain Delivery Module Brain Research Brain-Penetrant Drug BrainTransporter platform Brainshuttle Brendan Doran Brepocitinib Brexit impact Brian Armstrong BridGene Bristol-Myers Squibb Broad Institute Bruce D. Forrest Bullous pemphigoid Burden BurstDR C-reactive protein C-suite changes C3 G C3 complement inhibitor C3 glomerulopathy C5 inhibitor CAB CABA-201 CALD CALR gene CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-iNKT cells CB1 inhibitor CBI-1214 CBO CD CD20 Antigens CD20-directed therapy CD38 Antigen CD4 + T-cell CD47 Antigen CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CELMoD CEO resignation CEOs CETP CFO CHEK1 protein, human CHF CHORD trial CHW Access Act CIAS CLL CLL-313 CLL-314 CMS CMS Interoperability Framework CMT-SORD COMPOSE trial CORALreef CORALreef AddOn CORALreef Lipids CPI-refractory tumors CRB-701 CREM gene CRISPR CRISPR therapies CRO CROs CT-132 CT-996 CTMS CTPS1 inhibitor CTX310 CUE-501 CVR CX-2051 CXCR4 gene Cabaletta Cabaletta Bio Cabometyx Calcified (qualifier) Calico Califf California residents Calley Means Calquence Calypso study Cambridge Massachusetts Cambridge research labs Camurus Camzyos Canal Row Advisors Cancer Detection Cancer Drug Sales Cancer Risk Cannes Cantargia Capability Capital Expenditures Capital Markets Capricor Caps Capsida Biotherapeutics Carcinoma in Situ CardIQ Cardamyst Cardiac ablation Cardiff Oncology Cardiff University Cardiospermum grandiflorum Cardiovascular Agents Cardiovascular Risk Cardiovascular event Carl June Cartography Case (situation) Casgevy CatalYm Catalent Catalent Indiana Celea Therapeutics Celiac Disease Cell Culture Techniques Cell Differentiation process Cell Engineering Cell Shuttle CellCentric Cellares Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare and Medicaid Services Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cerebrovascular accident Chancery Change, Organizational Charcot-Marie-Tooth Disease Charles River Laboratories Chaudhuri Chechen language Checkpoint Therapeutics Cheryl Lubbert Chickenpox Vaccine Chief Commercial Officer Chief Financial Officer Chief Marketing Officer Chief Medical Officer Childhood Childhood Vaccines Children Program Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China-sourced asset Chinese biotech Chinese study Cholinergic Receptors Chondrosarcoma Chorionic Villi Sampling Chris Barry Chris Boerner Chris Shibutani Christophe Weber Chromatography Chronic Care Management Chronic Condition Chronic Inflammatory Demyelinating Chronic Obstructive Airway Disease Chronic lung disease Chronic sinusitis Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Circuit Cirrus Civil Rights Act Clarametyx Biosciences Claros facility Class II Medical Device Classical galactosemia Claudin 18.2 ADC ClearStrand-ASD Clearance Clearmind Medicine Click Therapeutics Clinical Equipoise Clinical Relevance Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline Clinician Cloning Vectors Clywedog Therapeutics Coartem Cognitive function: planning Coinbase Coleman Colonic Polyps Combined immunodeficiency disease Commercial Officer Commission approval Commissioner Committee Communication Communications Media Community Health Workers Comparative Efficacy Comparative Genomics Comparison Compass Compensation Committee Complement Inactivating Agents Complete Response Letters Comprehensive Computer Security Concentra Condition Conferences Confirmatory Trial Congenital Cytomegalovirus Infection Congenital deafness Congenital disorder of glycosylation type 1A Connecticut biotech Consumer Continuance of life Continuous Delivery Continuous Glucose Monitoring System Contraceptive Implant Contraceptive methods Corbus Pharmaceuticals CorestemChemon Corneal epithelial defect Correspondence as Topic Cosette Pharmaceuticals Cost Control Cost savings programs Court of Chancery Covalent Interaction Coya Therapeutics Craving for alcohol Creatine Kinase Creyon Criminal Justice Crisis Crohn 's disease Cryptigen CryptoMap platform Crystalys Therapeutics Ctexli Cu-Zn Superoxide Dismutase Cues CureVac acquisition Curevo Vaccine Curon Biopharmaceutical Cyprium Therapeutics Cyprumed Cytek Biosciences Cytology diagnosis CytomX Cytomegalovirus Infections DAWN DAZALS trial DCT gene DELIVER (veterinary product) DFO DLL3 DLL3 gene DLL3-targeting therapy DNA Methylation DNA Replication DNA Sequence DNA Sequence Rearrangement DOGE 's DOR/ISL DREAMM DREAMM-8 DT-101 DTC DTC Campaign DURAVYU DURECT Daily Dana-Farber Danyelza Dapiglutide Dark color Darovasertib Dasynoc Data Integrity Data Lakes Data Management Data Quality Data Science Data-Driven AI David Meek David Schenkein De Novo DePuy Synthes Deal Structure Decatur Illinois December 2025 Deciphera acquisition Deep Brain Stimulation DeepHealth Deerfield Deerfield Management Deficiency Degenerative polyarthritis Del-zota Demand (clinical) Dementia Research Institute Demis Denifanstat Dental Plaque Dental Solutions Departure - action Dermatologic disorders Dermatomyositis Desiree Cain Develop Developing Dexpramipexole Diabetes Therapy Diabetic Nephropathy Diabetic Retinopathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diastasis Diet, High-Protein Diffuse Glioma Digital Technology Digital Trial Digital innovation Digital therapeutics Dilution technique Dimitri Azar Diorasis Diphtheria-Tetanus-Pertussis Vaccine Direct-to-Consumer Advertising Disability Disasters Dispatch Bio Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Sara Brenner Draig Drug Approval Process Drug Compounding Drug Costs Drug Design Drug Kinetics Drug Negotiation Program Drug Overdose Drug Pricing Program Drug licensing Drug packaging industry Drug withdrawal syndrome Dry AMD Dry Eye Syndromes Duato Dynavax Dyne Therapeutics E. coli disease EASI EASI-75 EDIT-401 EDNRA gene ELEVATE-44 ELV001 EMBARK EMBARK trial EMBER-3 trial EMPEROR ENCELTO ENPP1 gene ENT1 ENaBL Platform EO-1022 EO-3021 EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EPI-321 ER-Positive HER2-Negative Breast Cancer ES-SCLC ESC25 ESK-001 ESSDAI ETA EUA EVO301 EVO756 EVOQ EXCALIBER-RRMM EXHALE-4 EY EZH2 protein, human Earendil Labs East Asian American East Asian Americans Economic Conditions Economic Growth Economics Edema Edenbridge Edison Oncology Editas Medicine Efruxifermin Eight Electroencephalography Electromechanical dissociation Electronic Electroporation Eledon Elektrofi ElevAAte Elevara Medicines Eli Lilly acquisition Eli Lilly competition Elinzanetant Eliquis Elix Eloralintide Elraglusib Elsa Emblaveo Emergency Situation Emergency Use Authorization Emi-Le Empaveli Empowered Empress Emrelis Enanta Enbrel Encapsulated (qualifier value) Encephalitis Encephalitis, St. Louis Encephalopathies Encryption End Point Endogenous Eneboparatide England Enhance (action) Enlaza Enrollment Enterprise Entity Enveda Environmental pool Enzeevu Enzyme Replacement Therapy Epcoritamab Epicrispr Epidemic Epigenic Epiminder Epitopea Equillium Equipment and supply inventories Erelzi Erica Palsis Erica Taylor Erik Atkisson Escalation EsoBiotec Essential Tremor Estimated Estrogen receptor positive Ethics Ethics Committees Etiome Eua (gastropod) Eukaryotic Cells European Medicines Agency Evaluate report Evan Rachlin Evernorth Evommune Evopoint Biosciences Evrysdi Ex-FDA ExPEC9V Exact brand biomedical or dental material Executive Board Exercise Exons Expanding Expedition Medicines Experience Experimental drug Expiration Exposome Express Scripts Extencilline Eye Drops Eye safety EyePoint EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FAERS FDA-approved therapies FDA/EMA regulatory pathways FL-501 FORTITUDE-101 FORTITUDE-102 FOXD3 gene FSP FUROSCIX FXR314 FXS6837 Facilities Association Facioscapulohumeral Factor XI Factor XI antibody Fair Language Proficiency Familial mitral valve prolapse Family suidae Fanconi Anemia Farapulse Faslodex Favored Fear (Mental Process) Federal Appeals Court Federal reduction-in-force statute Feedback - system communication Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fetal and neonatal alloimmune thrombocytopenia Fetus FibroGen 's Fibrodysplasia Ossificans Progressiva Fibromatosis Fibrosis Fibrosis, Liver Fill/finish Financial Stress Findable Fine - adjective Flare platform Flexible Flow Cytometry FlowMod FluidCrystal technology Food Policy Food Safety Forced Vital Capacity Formula - diet Fortrea Fosun Pharma Foundations Francis Frankfurt plant closure Frazier Life Sciences Free Mind ' Campaign Free Nurse Program ' Fujifilm Biotechnologies Functional improvement Fund I Futility Future FutureTech II G12C inhibitors G12D inhibitor GABA A GALA peptide GBS GCG GCG/GLP-1 agonist GDF8 protein, human GE HealthCare GE8820 GEMINI trial GH Research GH001 GLM101 GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1/glucagon GLPG5101 GM-2505 GMMA platform GMP violations GPCRs GRT-001 GS-1720 GS-4182 GSK 's GUB014295 GUBamy GUTC GXO Galapagos layoffs Galatea Bio Galaxies Galderma Gamma/Delta T-Lymphocyte Gardasil sales Garetosmab Garijo Gastroparesis Gateway Labs Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech Gene Expression Gene Expression Profiling Gene-Edited General Data Protection Regulation Generalized pustular psoriasis Generation Park Generations Generative Phosphoproteomics Genes Genetic Medicine Genetic Profile Genetic testing for cancer risk Genetix Biotherapeutics Genomic Orientation Genotype Genus Malus Genus: Coronavirus GeoVax Geographic Intersection Geographic Locations German language Germany Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gilgamesh Glenmark Glioblastoma Global Biobank Global Health Global Restructuring Global commercial operations Glucagon-Like Peptide 2 GlycoEra Glycomine Gossypium Gout Suppressants Government Shutdown Grabody-B Gram-negative bacteria Grand Prix Gray Delany Gregory Verdine Grin Gross (qualifier value) Groups Growth Differentiation Factor 15 Grünenthal Gubra Guidance 2024 Guillain-Barré syndrome Gumokimab Gurunathan GxP Gyre stock H5 avian influenza HER2- HER2-low HER2-positive carcinoma of breast HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER3 HERCULES trial HHS Overhaul HIF-2a HIV franchise HIV sales HOOKIPA HOPE-2 trial HOPE-3 trial HPV vaccine HR+ HRS-9821 HS-001 HS-20094 HS-20110 HSV-1 viral vector HTS HYMPAVZI Hahn Hair Analysis Hairy Cell Leukemia Haleon demerger Hallucinogens Hansoh Pharmaceutical Hansoh Pharmaceuticals Harbour BioMed Harmony Biosciences Harout Harris Lazarre Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya Hazard Ratio HeFH Health & Wellness Health Care Reform Health Care Sector Health Care Systems Health Data Research UK Health Equity Health Improvement Health Information Systems Health Personnel Health Services Research Health Services, National Health Workforce Health conditions:-:Point in time:^Patient:- HealthBench HealthCare Royalty Healthy America Hearing Heather Knight Helix (Snails) Hematologic Tests Hematology (discipline) Hemgenix Hemlibra Hemophagocytic Hemophilia A Hemophilia B Hepatitis, Alcoholic Hereditary Hereditary Diffuse Leukoencephalopathy with Spheroids Heterogeneity Hidradenitis High Drop-Out Rate High dose High-Frequency Microsatellite Instability Highest Hikal HilleVax Hillhouse Capital HistoSonics exit Hoist device Holistic epilepsy management Honeymoon Effect Hong Hookipa Pharma Hormone Therapy Hospital admission Hospital specialist House Appropriations Committee Houston Human Glandular Kallikrein 2 Human Services Secretary Humanitarian Exemptions Humira patent expiration Hungary Huntington Disease Hypercholesterolemia, Familial Hypercon Hyperphosphatemia (disorder) Hypersensitivity Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy without obstruction Hypocupremia Hypoglycemia Hypothalamic obesity IBC IBI343 IBI363 IBTROZI ICER IDO1 IDS gene IDWeek IDeate-Lung01 IGF1R gene IGNYTE trial IGYNTE II IL-17A monoclonal antibody IL-23 receptor antagonist IL-31 receptor alpha IL1RAP antibodies IL1RAP protein, human IL31RA gene IMM2510/AXN-2510 IMNN-101 IMVT-1402 IMforte trial IMvigor011 INAVO120 INBRX-101 INF904 INHBE gene INLIGHT trial INZ-701 IPG IQVIA IRAK3 gene IRAK4 gene ISAC ISB Iambic Icebergs Ichnos Glenmark Ideaya Biosciences Idorsia IgG4-Related Disease IgM antibodies IkT-001Pro Illinois (geographic location) ImCheck Therapeutics Imbruvica Imlunestrant Immune Immune Activation Immune Medicines ImmunityBio ImmunoPrecise Antibodies Immunocompromised Host Immunoglobulin IgG4 Immunoglobulin M Immunologic Adjuvants Impacts, Environmental Impaired cognition Improved Improving (qualifier value) Imsidolimab Imunon In complete remission Inavolisib Incentives Incheon Inclusion India 's Indiana Indianapolis Indivior Induce (action) Infant, Newborn InflaRx Inflammatory disorder Inhaler Inhibikase Initiative Injection of therapeutic agent Inluriyo InnoCare Inobrodib Inozyme Inspection (procedure) Inspira Technologies Instill - dosing instruction imperative Instrument - device Intas Intelligence Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interius BioTherapeutics Interleukin-2 International Aspects International Drug Prices Interoperability Interoperable Interventional procedure Intervertebral Disc Degeneration Intravascular Investigational New Drugs Invivyd Ipsen Iptacopan Irish (ethnic group) Ironwood Israeli (population group) Itovebi Ixchiq vaccine J.P. Morgan Healthcare Conference JAK/SYK inhibitor JAM JAMA study JCR JN.1-lineage JNJ-2113 JNJ-4496 JPY JS005 JUST-AAV Jacqueline Corrigan-Curay Jamie Janssen Vaccines Janus kinase 1 Japanese language Jascayd Jeavons syndrome Jeito Jemperli Jerome Jersey pharma Jersey site Jigani Facility Joaquin John Carroll Johns Joint Atomic Model June Junshi Juvenile KARDIA-3 KAT5 wt Allele KB801 KCNT1 gene KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 trial KIT KKR KMT2A gene KOL Bulletin KOMET-017 KP.2 strain KPI-012 KRAS KRRO-110 KT-621 KYV-101 Kaerus Kai Beckmann KaiSR Kaken KalVista Kala Bio Karen Smith Karyopharm Therapeutics Kate Walsh Keith Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keytruda Qlex Keytruda head-to-head trial Keytruda patent Kezar Life Sciences Kidney Kidney Failure Kidney Failure, Acute Kim Kin-Hung Peony Yu Kinevant Kisqali Kissei Kit device Kite Pharma partnership Kite, device (physical object) Kleiner Knee pain Kong Korean language Korro Bio Kostaive Kowa Krazati Kresladi Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kura Oncology Kymab Kyowa Kirin Kyverna LAVA-1266 LBCL LBP LBRX LDLR gene LENZ LGBTQ+ professionals LP.8.1 sublineage LRP4 gene LUMRYZ LUNA 3 trial LX9851 LYT 100 LaNova Medicines Labcorp Labor (Childbirth) Landscapes Languages Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Latex Fixation Tests Latigo Latozinemab Launch-HTN Lawrenceville Leaked Legal Case Legal Challenges Legend Biotech Lenvima Lepodisiran Lesion Leukocyte adhesion deficiency type 1 Libertas Bio Libertyville Illinois License Agreement Life LifeMD LifeMine LifeSignals Lifespan Extension Lifetech Lifting Lilly 's Lilly collaboration Lilly partnership Limitation Limited stage (cancer stage) LinusBio Lipid Metabolism Disorders Lipids Lipoidosis Lipoprotein(a ) Liquid Biopsy Lithotripsy Livdelzi Live Biotherapeutic Product Liver and Intrahepatic Biliary Tract Carcinoma Liver damage Logica London London Bioscience Innovation Centre London Cancer Long-Term Strategy Longevity Longwood Fund Lotte Lower Profile Lukácsháza Lumakras LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit AI Lupus treatment Lutathera Lymphocyte Count measurement Lymphocytes Lymphodepletion Therapy Lymphohistiocytosis Lymphoma, Follicular Lynozyfic Lysosomal Storage Diseases Lytenava M growth fund M&A activity M.D. M6495 MACE-3 MADRS score MC4R MCED MDM2 Antagonist ASTX295 MEERKAT trial MESA MET protein MHRA MIT MMRV vaccine MOG antibody disease MR-139 MRD MRM Health MSH5 gene MTLE MWT MacTel Machado-Joseph Disease MacroGenics Madness Magnet <device> Mahery Maker (occupation) Malignant Bone Neoplasm Malignant neoplasm of anus Malignant neoplasm of thyroid Manfidokimab Manihot esculenta MannKind Mantle cell lymphoma Manufactured Supplies Manufacturer Manufacturing costs Marco Rubio Marengo Marietta Pennsylvania Mark McLellan Markers (device) Martes pennanti Martin Martin Makary Mary-Elizabeth Maryland (geographic location) Massachusetts biotech Massive Mastocytosis, Systemic Matchpoint Therapeutics Matt Buckham Mayne Mazdutide Measles-Mumps-Rubella Vaccine Measurement Mechanism (attribute) MedSurg Medicaid block grants Medicaid fraud Medical Imaging Medical service Medicare fraud Medicare reforms Medtronic Megarounds Meister Melanoma TRP2 CTL Epitope Vaccine SCIB1 MenABCWY Menstruation Mental Recall Mental association Mentorships Merck 's Mersana Metals Metapneumovirus Metastasis from malignant neoplasm of colon and/or rectum Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Prostate Carcinoma Metastatic to Metis people Michael Langer Michael Rogers Microbial Microbiome SER-155 Microbiome therapeutics Mikael Mike Hershkovitz Mild cognitive disorder Milestone Miller Dieker syndrome Minder system Minghui Minimal Residual Disease Negativity Mirum Misleading Drug Ads Mitigation Strategy Mitochondrial Diseases Mitsubishi MoSEIC Modernization Modeyso Modic Molecular Clamp technology Molecular Imaging Molecular Targets Monarez Monte Montes Montgomery-Åsberg Depression Rating Scale MoonLake Immunotherapeutics Morbidity - disease rate Morgan Stanley Morristown Mother (person) Motion Sickness Mourenx Movantik Move GBS Forward™ Movement Mucopolysaccharidosis Type IIIA Multiple Sulfatase Deficiency Disease Mumps Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle-Boosting Drugs Musk Mycobacterium tuberculosis Mycoses Myeloid cell engager Myositis Myotonic Dystrophy N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide NAION NAMs NDA filing NECTIN4 gene NEFL gene NEPTUNUS-1 NEPTUNUS-2 NGM NGN-401 NHS England NIH layoffs NINL gene NK1/NK3 receptors NLRP3 inhibitor NON Mouse NP-MP1 NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NUCLIDIUM NUSAP1 gene NUZ-001 NVIDIA 's NX-3911 NYSE Nabla Bio Namandjé Bumpus NanoDisc NanoPhoria Nasal Spray Nasal drug delivery Nasdaq Stockholm Natera National Association of National Cancer Institute National Priority Voucher National Resilience National Security Commission Negative Predictive Value of Diagnostic Test Negotiation Program Nektar Therapeutics Nemluvio Nemvaleukin Alfa Neo-1 Neoantigen Neomorph Neoplasm Metastasis NeuralPLexer Neuregulins Neuro Disease Neurocrine Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurogene Neuroinflammation Neuropsychology Neurosteroids Neurostimulation procedures of spinal cord tissue Neurotrophic keratitis New Approach Methodologies New York Stock Exchange New-onset refractory status epilepticus NewAmsterdam NewBridge Pharmaceuticals NewLimit Newborn Nexplanon NextCure NextRNA Nextstellis Nia Tatsis Nick Vatakis Nicole Verdun Nimacimab Nimbus Nipocalimab Nkarta Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Noninvasive Endpoint Nordisk alliance Nordisk facility North Chicago Nosis Novartis-Chinook acquisition Novo Nordisk Foundation NovoCare Nucleus RadioPharma Nuvalent Nuvation OBBBA OBT OCT50 OFA OLN324 OMass OPKO OPTIMA trial ORR OSE Immunotherapeutics OTOF gene OTX-201 OX40 receptor OXPHOS pathway Obefazimod Obesity Trial Obexelimab Obstructed Ocaliva Oceanside Ocedurenone Ocrevus OdyssION platform Odyssey Therapeutics Office Officer David Rose Offit Ogilvy Health Ohtuvayre Ollin Ollin Biosciences Omeros Corporation Omicron Omicron JN.1 Omniverse Onapgo Oncologic Drugs Advisory Committee Oncology Focus Open Operating Operational streamlining Ophthalmological implant Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optimism Optinose Opvee divestiture Oral Medicine Orals Orano OrbiMed Orbital Therapeutics Order Tubulidentata (organism) Orexin Receptor Agonist Organ Shortage Organisation for Economic Co-Operation and Development Organization administrative structures Organon Organovo Orionis Biosciences Ornithine carbamoyltransferase deficiency Orotecan Orphan Cures Act Orthopedics Otsuka 's Otsuka Holdings Otsuka Pharmaceutical Overweight Ownership Oxford BioTherapeutics Oxford Finance Oxycontin P-Value PADOVA study PB212 PBA PCED PCSK9 protein, human PCVs PD-1/VEGF bispecific antibody PD-1xVEGF bispecific PDE3/4 inhibitor PDUFA VIII PET/CT scan PF-06954522 PF-ILDs PFAS gene PGI PI3 K pathway PIK3CA mutation PIK3CA/AKT1/PTEN pathway PIPE financing PIVOT-PO trial PKMYT1 protein, human PKP2-associated cardiomyopathy PLK1 gene PM359 POETYK PP353 PP405 PREVAIL trial PRISM BioLab PRX012 PTAB PTH1R gene PURPOSE studies PYRUKYND Pacira Pain Palynziq Pancreatitis, Acute Pandion Paratek Parker Institute for Cancer Immunotherapy Parkinson 's Paroxysmal nocturnal hemoglobinuria Paroxysmal supraventricular tachycardia Participant Partnering Pasadena Patent extension Pathology Patient Protection and Affordable Care Act Patient location type - Department Patient-Centered Patrizia Cavazzoni Paul Edick Pavblu Pelage Pemgarda Pemphigus Vulgaris Pennsylvania site closure PepMetics Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perkins Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personality Character Personnel Turnover Perspective Pet Animal Peyronie 's disease Pfizer 's Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer-BioNTech Phage Therapy Phagocytosis Pharma AI Pharma Acquisition Pharma Concessions Pharma Tariffs Pharma import taxes Pharmaceutical Group Pharmaceutical Ingredients Reserve Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Phase Phase 1 - 2a Phase 1/2 trial Phase 1b trial Phase 2a Trial Phase 2a trial Phase 2b SYMMETRY Phase 2b trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase I Phase I – III study Phase III AURORA trial Phase III Essence study Phase III MARIPOSA trial Phase III REGENCY trial Phase III ZENITH trial Phenylketonurias Philips Phoenix Arizona Physical activity Physical and emotional exhaustion state Physician Executives Physicians Pick Disease of the Brain Piclidenoson Pioneer Antibody Discovery Pioneering Medicines Pipeline Strategy Pivotal Plants Plaque (lesion) Plexiform Neurofibroma Plozasiran Poisons Polycythemia Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Pooled Sample Portfolio diversification Positive Post-Hoc Live Post-Pandemic Downsizing Post-bankruptcy consolidation Practice Experience Prasad 's Prasinezumab Pre-Exposure Prophylaxis Pre-filled Syringe PreCheck Prealbumin Prediction Pregnanolone Prescription Drug Overuse President brand of dental material Presidential Symposium Preventive Care Previous Primary Health Care Primary hyperoxaluria Prime Medicine Principles Priovant Private financing ProFound Therapeutics Probiotics ProfoundBio Progranulins Projections Promotion (action) Protection Protein Engineering Protein Kinase C Protein Kinase C Inhibitor Protein Purification Protein Tyrosine Kinase Protein-Protein Interaction Proto-Oncogene Proteins c-akt Provider Proximity Prurigo PsA-2 trial Pseudobulbar affect Psoriatic Public Health Trust Public Listing Pulmonary Eosinophilia Pulmonary veins Purchase Purchased Services, Clinical and Biomedical, Research Purdue PureTech Pyoderma Gangrenosum Pyzchiva Q1 trends Q2 layoff Q2 sales QUC398 QuEEN Quality of life Qyuns Therapeutics R&D strategy RAPT RAS RAS cancer RAS-addicted cancers RAS/RAF inhibitor RCT RDEP RDX-002 RE104 REACH-DMD study REACtiVe-2 RENOIR RFK Jr. rhetoric RGX-111 RIFs RIPK2 RIPK2 scaffolding inhibitor RNA Splicing RNA Vaccine RNA delivery RNA drug RNA medicine RNA medicines RNA technology RNA test RNA, Circular RNA-targeted medicine RNA-targeting ROR1 protein ROR1 protein, human ROS1-positive Lung Cancer ROS1-positive NSCLC RRP RSV vaccine RTU cartridges RVU120 Rachael Racism RadNet Radiance Biopharma Radionuclide therapy Raised Rallybio RLYB212 Rani Therapeutics Rating (action) Readiness Reading (activity) ReadyFlow Autoinjector Receptors, Islet Amyloid Polypeptide Recognify Life Sciences Reflex Refractory Plasma Cell Myeloma Regeneron Pharmaceuticals Regulation of biological process Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory T-Lymphocytes Reimbursement Reindeer Reinvention Relmada Relyvrio RemeGen Remote control command - Clear Renal Cell Carcinoma Renal function Renalys Rentschler Repare Repertoire Report (document) Research Infrastructure Research Organization Research Projects, R-Series Research Triangle Park Reshma Kewalramani Resistance (Psychotherapeutic) Resources Restricted Resumption Retifanlimab Retinal Vein Occlusion Retinoschisis Retrotransposons Return to (contextual qualifier) (qualifier value) Reunion Reunion Island Revenue Decline Revenue Milestone Reverba Global Reverse Stock Split Revolution Vibe CT Revuforj Rezdiffra Rezon Bio Rezpeg Rezpegaldesleukin Rezurock Rhapsido Rhode Island Rhythm Richard Richmond Ridgefield New Jersey Rinvoq growth Risdiplam Risk Management Rob Michael compensation Robert Langer Roche 's Rocket Pharmaceuticals Roctavian Rogaine Roger Perlmutter Ross Haghighat Rotation Royalty Pharma Rubella Russia Ryan Richardson Rybelsus Rytelo Ryvu Rznomics SANDCAT trial SAT-3247 SAVITRI SB-01 SC0062 SCLC SCN10A gene SCOPE IO SCOPE trial SEC SEP-786 SERENA-6 trial SERON SGR-2921 SGT-003 SHP-DB1 SIM0505 SLC17A5 gene SLC6A8 Inhibitor RGX-202 SMA SNCG gene SPAG8 gene SRP-1003 SRP-9003 SRSD107 SSGJ-707 STAT6 STAT6 degrader STAT6 protein STELLAR-303 trial STI-based STX-001 STXBP1 gene SURMOUNT-5 Trial SURPASS-CVOT SURPASS-PEDS SURVEY.ALSFRSR SV Health Investors SYD-101 Sackler family SafeBeing platform Safety Issues Sagimet Sail Biomedicines Samsara Samsung Bio San Diego Sanjay Sanofi Strategic Sanofi Ventures Sanofi acquisition Sapablursen Saphnelo Sapio Sapio Sciences Sarah Boyce Sarbani Sarcoidosis, Pulmonary Sasanlimab Satellos Saxenda Scancell Scheme of Arrangement Schott Science of genetics Scientific Data Scientific Study Scorpions Scott Gottlieb Scripps Research Sebetralstat Secondary malignant neoplasm of pancreas Section 232 Security - service Security Measures See-Mode Selective Estrogen Receptor Down Regulator Self-Injectable Self-injection Semerjian Senators Senile cardiac amyloidosis Sensorineural Hearing Loss (disorder) Sentynl Sentynl Therapeutics September 23 Sequestration Serbs Seres Series A financing Series B fundraising Series C Series C financing Series C funding Seronegative Shanghai Shankar Ramaswamy Shapes Shareholder Ownership Structure SheMed Shigella Infections Shigella Vaccines Shingrix competitor Ships Shock Shockwave Medical Shooting sensation quality Short Bowel Syndrome Sickle Cell Siemens Healthineers Signatera Simcere Simplexvirus Simufilam Single Agent Therapy Sirexatamab Sirius Sirona Medical Sironax Sitala Site Closure Site of exit Sjögren 's disease SkyEngine Skyrizi Sleep Apnea, Obstructive Sleep disturbances Sleep medicine specialist Solid Biosciences Solutions Solventum SomaLogic Somatix Sotatercept South San Francisco Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Spectrum Profiling Spero Therapeutics Spevigo Spine BioPharma Spinout Spiriva Respimat Spondylarthritis SpyLock technology SpyTag/SpyCatcher Squamous cell carcinoma Squamous cell carcinoma of skin Squibb Layoffs Squibb partnership Standard BioTools Star Therapeutics State Room Status Quo Stemchymal Step Pharma Stephen Hemsley Steve La Neve Steve St. Onge Steve Tomlin Stevenage facility closure Stimulation procedure Stivarga Stock Reaction Stoke Strategic Deals Strategy Stuart Pharmaceuticals Stéphane Bancel Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Sun Pharma SunRISe-1 trial Suneet Varma Super Bowl 2025 Super Bowl ads Superluminal Medicines Supernus Supplement Supply chain disruption Support Services Program Supranuclear paralysis Supreme Court Supreme Court stay Surgeon Surgical Replantation Surrogate Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter Swissmedic Swixx Group Sydnexis Syfovre SynAIRgy Synbio International Inc. Syndax Syndeio Syphilis, Congenital SystImmune T business T-Cell Receptor T-cell malignancies T-cell therapy TAF8 wt Allele TAILORED-AF TAK-861 TALAPRO-2 TAS-205 TETON-2 THB335 TIDAL-01 TIGIT antibody TLN-121 TLN-254 TLN-372 TLX2 gene TNBC TNFRSF4 gene TP53 gene TPRG1L gene TRANSCRIPTION FACTOR TRBV9 gene TRIM21 TRIMTAC TRONTIER TRPV4 protein, human TRiM platform TSHA-102 TSLP gene TSND-201 TTAM TUB-030 TUB-040 TULIP-SC trial Tablet Dosage Form Takhzyro Tampa Florida Tang Tanruprubart Targeted Therapy Taxes Taysha Gene Therapies Team Tech Rivalry Ted Love Tedopi Teijin Television Telix Tempus AI Tender Tenvie Termination - Inactive Reason Code Tessera Testiculo- Testing Texas Facility Thalassemia Theranostics Therapeutic Antibody Therapeutic immunosuppression Thick Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomson Reuters Thousand Oaks Thyme Care Thyroid Diseases Thyroid associated opthalmopathies Tiragolumab Titles Tonix Tonmya Topco Total Improvement Score Tourette 's syndrome Tourmaline Bio TraceNET Tracer Tradipitant Transcarent Transfection Transfer RNA Transformational Data Transforming RNA Medicine Development Translarna Transplantation Transposition of Great Vessels Trastuzumab Rezetecan Treating Treatment Effectiveness Treatment Protocols Tregs Tremfya Trial Phase Trial Termination Trimonthly Trinity (ethnic group) Trontinemab TruTCR Trulicity Trump 's Trump administration reforms Trump administration tariffs Trump import tariffs Trump tariff Trust (Social Behavior) Truvada Tubulis Tumor stage Tis Tumor-Infiltrating Tumorigenicity Tyvaso UBT251 UCB UK 's UNLOXCYT UPCR US-China competition US-EU UX111 UgeneX Ultragenyx United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal University of California Unresponsive to Treatment Unspecified Abortion Updates Uplizna Uptake Urinary Bladder Urinary hesitation Urology Urticaria VAERS VAL-413 VALOR study VAV1 protein VAX-24 VAX-31 VAY736 VENT-02 VESALIUS-CV VESALIUS-CV trial VGA039 VIZZ VMX-C001 VRDN-003 VTCN1 gene VX-993 VY9323 VYJUVEK Vaccination Hesitancy Vaccine Development Vaccine Reform Vaccine Testing Vaginal Microbiome Validation Valiltramiprosate Valinor Valo Health Vamikibart Vanda Vanrafia VantAI Variant Variation (Genetics) VarmX Vas Narasimhan Vascular Diseases Vaseline Vasudev Bailey Vaxcyte VectorY Veklury VelaVigo Vemircopan Venclexta Ventus Therapeutics Veradermics Veraxa Verification Verona Pharma Versant Vertex Veru Verzenio Vestibulo-Ocular Viable Viatris Vibrance-1 study Vicebio ViewPoint EchoPilot Viewer Device Vigil Neuroscience Vimseltinib Violence Viome Virginia Virginia plant Viridian Virus-Like Particle Visible Vistagen Visugromab Vital capacity Vital capacity test Vomiting Vor Bio Voucher Vunakizumab Vykat Vykat XR Vyvanse Vyvgart Hytrulo WARN WARN filing WARN notice WEE1 WEE1 gene WEE1 inhibitor WHIM syndrome WVE-007 WVE-N531 Wakefulness Wakefulness Test Walmart partnership War-Lock platform Warsaw-Duchnice Washington state Wearable Behavior Model Wearable Electronic Devices Web Site Weldon Weldon 's Welireg Wellcovorin Werner Syndrome Wet AMD Wet Age-Related Macular Degeneration White House liaison William Blair Wilmington Wolfgang Wienand Women Workforce Workforce - population group Working Group World WorldMeds Wounds - qualifier Written - Consent Mode Wuhu X-Linked X-linked retinitis pigmentosa XHANCE XLRP XOMA Royalty XR Xanthomatosis Xarelto patent Xenograft procedure Xolremdi Xspray Pharma XtalPi Y-mAbs Yale Yervoy Young Adult Yvonne Greenstreet Z-1018 ZENITH trial ZUSDURI ZW171 Zag Bio Zai Lab Zealand Pharma Zemaira Zentalis Zepzelca Zilebesiran Zilganersen Zilovertamab Zongertinib Zoë Zuellig Pharma Zymeworks Zynlonta Zynyz aDBS aTyr abbott abelacimab access program access strategy accessible aceclidine acquisition acquisition termination active pharmaceutical ingredients activin signaling acute liver injury acute systemic infection ad campaign adaptive deep brain stimulation adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment administrative law adulteration advanced breast cancer advanced manufacturing advisory affairs aficamten age restriction age-related diseases agency departures agency staffing shortages aging-related diseases aldosterone synthase inhibitor all-cash tender alliance allogeneic hematopoietic stem cell transplant with purging alpha radioligand therapies alpha-Synuclein alpha-synuclein antibody alternative testing alternatives altretamine/cisplatin/cyclophosphamide protocol ambulatory care services amendment amezalpat amivantamab amsacrine/azacitidine/etoposide amycretin amyloid beta antibody amyloid-beta amyloid-lowering drug anifrolumab anti-VEGF therapy anti-vaccine movement antiarrhythmic peptide antibody design antibody engineering antibody-chopping drug antisemitism antisense antithrombin III antitrust apomorphine hydrochloride applicability application assessment approval status aroxybutynin artemether-lumefantrine artificial luciferases aseptic manufacturing asset termination assumes assurance at-home at-home colon cancer atomoxetine attractiveness auction autoimmune drugs autonomous avacincaptad avibactam azacitidine aztreonam belumosudil bemarituzumab benefit-risk profile bespoke bevacizumab bidding war bile acid therapy biliary cholangitis bimagrumab biochemical recurrence bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomarker test biomarker testing biomedical foundation models biomedical innovation biomolecular structure prediction biopharma exit strategy biopharma financing biopharma job biopharma regulation biopharma startups biopharma survey biopharmaceutical company biopharmaceutical innovation biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups bioprocess bioprocessing biosimilar competition biotech careers biotech closure biotech collaborations biotech dealmaking biotech employment biotech finance biotech financing biotech incubator biotech leadership biotech licensing biotech spinoff biotech strategy biotech workforce biotechnology layoffs biotechnology partnerships bipartisan criticism bird flu vaccine birtamimab bispecific antibody screening bispecific antibody technology black-box warning blockbuster sales blocker blood clotting drug blood thinner board chair board changes bone lesion prevention booth bortezomib bota-vec brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name drugs brand-name prescriptions bretisilocin broaden business career business options business split business strategy butyrophilin superfamily cGVHD cUTIs cabotegravir calcium calcium glucarate camizestrant campaign campaigns cancellations cancer antigen therapy cancer testing cancer therapeutics cancer treatments capacity quadruple capital constraints capivasertib capsule (pharmacologic) cardiac research cardiometabolic care cardiometabolic disease cardiorenal medicine cardiovascular benefits cardiovascular gene therapy cardiovascular safety cardiovascular trial cargo receptor ligand activity cartilage degradation carve-out casdatifan cash position cash-paying cell analysis cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-device combo cell/gene therapy cemdisiran central subfield cerebrotendinous xanthomatosis charmed checkpoint inhibitor-resistant chemical alternatives chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hives cisplatin-ineligible civil claims class action clean sweep clemidsogene lanparvovec click clinic entry clinical holds clinical remission clinical reproducibility clinical research services clinical strategy clinical terminology clinical trial conduct clinical trial halt clinical trial results clinical worsening clinical-stage clinicogenomics clofutriben clone stability co-development co-location cognition cognitive improvement cold chain logistics collaborative framework collaborative healthcare commercial strategy commercial supply chain commitment community grants company closure company transformation competitive weight loss medication competitiveness complement system computational drug discovery computational protein design concessions conditional approval pathway conditioning regimens confidentiality confirmatory study conservative criticism conspiracy constitutional challenge constitutionality content intelligence contingent value contingent value right continuous continuous glucose monitor contract cancellation contract extension contract manufacturer controllable convertible copper isotopes corneal endothelial disease corporate development cost management cost-cutting initiatives cost-effectiveness cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry coverage - financial contract crash credit card fees critical bleeding cross-border pharma ctDNA-guided therapy customer-facing organization customs loophole cutaneous remission cyclobenzaprine cynicism cytisine daisy daraxonrasib data bottlenecks data manipulation data misinterpretation data modernization data secrecy data-driven decisions data-driven innovation datasets dazucorilant deal activity deal termination death risk reduction debt debt maturity extension deceptive marketing decision delay decision science deficiencies degraders delgocitinib demerger dencatistat denosumab deprioritization deruxtecan-nxki device regulation digital health records digital infrastructure digital medicine digital quality systems digital solutions digital tools dimethylethylsilylimidazole direct-to-consumer ( DTC ) director firing disability services discontinued disease activity disease control rate disease drug disease prevention disease program disease treatment disease treatments disease-modifying treatment divestiture dividend docetaxel domestic pharmaceutical industry domestic production doravirine/islatravir dostarlimab dotinurad doubt downturn draft report drug acquisition drug activity drug ads drug application drug approval outlook drug competition drug conjugates drug delivery innovation drug discontinuation drug discount program drug discounts drug failure drug import duties drug importation drug imports drug ingredients drug lag drug manufacturers drug pipeline drug pricing plan drug production drug quality drug rebates drug relabeling drug reviews drug sales drug spending drug-resistant drug-resistant epilepsy drug-resistant focal seizures dual-payload technology dual-targeting dulaglutide dupilumab eGenesis eRNA early disease early-stage trial efdoralprin alfa efimosfermin alfa efzofitimod elenestinib elinzanetant emiltatug ledadotin employee layoffs employment employment reduction enfortumab engine enlicitide enlicitide decanoate enobosarm entera enterprise reorganization environmental enzyme engineering enzyme restoration enzyme technology epigenetic modulator epigenetic reprogramming epigenetic therapy equity esreboxetine estate etanercept etripamil exacerbations exagamglogene autotemcel exclusivity extension executive actions executive appointment executive appointments executive changes executive promotions executive survey executive team executive transition existential threats exophthalmos producing substance expanded label expansions experts external partnerships eye treatment facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen fast-track approval faster federal agencies federal courts federal directives federal workers fee structure fentanyl fibrodysplasia fibrosing field ablation figures filing checklist final analysis financial financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles firi-cel first-in-class first-in-class antibiotic first-line fiscal flagship office flu/COVID-19 foreclosure proceedings foreign factories formula update formulary exclusion formulations franchise fratricide-resistant full-year guidance function funding lapse gMG gains garadacimab-gxii gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastroesophageal adenocarcinoma gastrointestinal gemcitabine gemcitabine intravesical system gemcitabine releasing system gene modulation generative design generic competition generic manufacturing genetic cell genital lesion reduction genomic analysis genomic medicines gepotidacin global commercialization global competitiveness global drug development global growth strategy global headquarters global health programs global license agreement global price global sales global strategic R&D center global strategic partnership global strategy global trade tensions glucagon go-to-market models golimumab government programs government review governmental engagement grace granite grant cancellation green energy green list green manufacturing growth opportunities growth strategy guidance cut guidance raise guidance upgrade guidances gusacitinib hair loss treatment halt harassment head-to-head trial headcount health coverage health data health prediction health system partnerships health systems health workers healthcare agencies healthcare appointments healthcare benchmark healthcare budget healthcare changes healthcare finance healthcare financial performance healthcare legislation healthcare marketing trends healthy lifespan heart drug heroin herpesvirus 2, human high-performance computing high-throughput high-throughput screening hold-and-kill homegrown hospital intervention human papillomavirus huntingtin-lowering hyaluronidase iMTP iRhythm iSCIB1 + iberdomide icotrokinra ifinatamab illegal immigration iluzanebart image management immune compromise immune disorder therapy immune profiling immune protection immune system reprogramming immune-mediated diseases immunoglobulin G immunotherapeutics impairment charges implantable device implementing import rules import taxes improvements in situ in vivo studies incretin drugs incretin therapy indictment individual choice individual-based decision-making induction trials infringement inhaled lung disease inidascamine initiation protocol innovation centre insider trading interleukin-11 interleukin-12 interleukin-23 interleukin-3 intermediate-risk international operations international pricing international trade internet phrase intra-abdominal infections intrathecal delivery intravenous formula investor sentiment investors islet isolator technology isononanoyl oxybenzene sulfonate issues itolizumab ixovec iza-bren judgment kickback scheme kidney drug kilobase pairs kinase inhibitor [EPC] label extension label update labeling changes lack of lack of transparency lanifibranor laru-zova late-stage assets late-stage clinical development late-stage testing layoff leaders legal victory lender takeover lentiviral vectors leucovorin leuprolide license suspension licensing restrictions life-extension life-saving medicine likeability liraglutide listings live event liver enzyme elevation lobbying localization locally advanced head long-acting long-acting injectable long-acting injectables long-acting protection long-acting therapies long-acting therapy loss treatment lotiglipron low low-cost low-grade lung scarring lurbinectedin lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mNEXSPIKE mRESVIA mRNA cancer mRNA contracts mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based macroeconomic macular maintenance trial management layers mandates manufacturing capacity manufacturing challenges manufacturing consolidation manufacturing deficiencies manufacturing license manufacturing practice manufacturing uncertainty marketing officer match Eylea measles, mumps, rubella, varicella vaccine measurable outcomes med-tech medical AI medical advancements medical device company medical freedom medical groups medical review medical supplies medical supply chain medical technology medical technology exemptions medtech industry meeting cancellation mega depots melanin-concentrating hormone membranoproliferative glomerulonephritis men 's health mental health innovation merger agreement merger cancellation mergers mesothelin metabolic dysfunction-associated steatohepatitis metabolic health metabolic medicines metagenomic sequencing methionine mezigitamab microenvironment microparticle technology microservices mid-stage middle dose middle-income countries middlemen midline glioma milestone payment milestones minimis exemption minimization missed milestone mitazalimab molecular entities molecular glues molecular residual disease month most-favored most-favored-nation pricing motor fluctuations motor milestones mouse models multi-agent system multi-cancer early detection multi-institutional research multi-medicine platforms multi-omic strategies multi-payload multi-sensor multi-year collaboration multibillion-dollar market multiforme multimodal AI muscle health muscle loss muscle preservation muscle strength endpoint musculoskeletal conditions naloxegol nano-in-micro delivery nanobody nanodelivery nanoparticle delivery naproxen-n-butyl nitrate narsoplimab nation policy national priorities national priority review vouchers national sector growth nations nature-inspired drug discovery navenibart negative opinion negotiators nemolizumab neo-epitope cancer vaccine neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurofibroma neuropsychiatric drugs neutrophil-mediated disease newco next-generation Covid vaccine next-generation biologics next-generation sequencing next-generation vaccine nintedanib nipocalimab-aahu nizubaglustat nmHSPC nodularis nomination non-European ancestry non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-hormonal therapy non-inferiority non-mRNA vaccine non-metastatic non-opioid pain medication non-opioid pain relief non-surgical back pain noncirrhotic nonsurgical treatment options normative wakefulness nusinersen oHCM obesity-related cancers ocular adverse events ocular immunology off-target offloading omnichannel on-demand once-monthly once-yearly oncology advancements oncology company oncology ecosystem oncology expert oncology licensing deal oncology partnership oncology pivot oncology portfolio oncology therapeutics oncolytic immunotherapy online program onvansertib open-source AI open-source dataset openFDA operating profit margin operational efficiency operational transformation ophthalmic preparation optimisation programme oral FASN oral PCSK9 oral asthma therapy oral carbapenem oral drugs oral formulations oral inhibitors oral obesity drug oral peptide oral peptides oral pill vaccine oral regimen oral small molecule oral small-molecule therapy oral weight loss drug orchestration orelabrtuinib orexin agonist organ donor orphan drug exclusion osavampator ossificans otoferlin out-licensing overall response rate overcapacity overhaul overhype overmedicalization overseas oversubscribed fund ozekibart p-tau217 p300/CBP inhibitor pamirtecan pan-JAK inhibitor partial response partnering with partnership termination pasritamig patent cliffs patent expiration patented drugs patient navigation patient-specific therapies patient-specific therapy patritumab pause recommendation payer paying payload pediatric brain cancer pediatric drug designation pegol pemvidutide penicillin recall personal data personal genome service personal reasons personalized cancer therapy personalized neuromodulation personalized therapies personnel change perspectives pertuzumab pharma TV ads pharma innovation pharma packaging pharma policy pharma trade group pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical communications pharmaceutical delays pharmaceutical divestment pharmaceutical employment pharmaceutical imports pharmaceutical licensing pharmaceutical manufacturers pharmaceutical market pharmaceutical mergers pharmaceutical milestones pharmaceutical partnership pharmaceutical rebates pharmaceutical revenue pharmaceutical setback pharmaceutical trade war pharmacy platform pharmacy reimbursement philanthropy phosphodiesterase 4B pimecrolimus pipeline cull pipeline focus pipeline gaps pipeline restructuring pipeline shake-up pipeline shift pipeline update pivot resources pizuglanstat plant construction plasma-derived therapy platelet levels platinum-resistant plunge pneumococcal conjugate vaccines political portfolio companies portfolio reprioritization portfolio support post-COVID postprandial povorcitinib practice-changing pre-IPO ' preclinical CRO preclinical drug preclinical pipeline preclinical program predictive models pregnancy detection premium presbyopia prescribing habits prescription drug ads prescription drug costs prespecified preventive services panel price decline price hike prime editing prioritization private block trade private placement product hopping profit margin progressiva project cancellation propane propiolactone protections protein compounds protein folding protein levels protein-based vaccine protocol design pseudobulbar psychedelic medicine public biotech public companies public company public health agencies public health crisis public health guidance public health leaders public servants pumitamig pure-play strategy quality assurance quality control violations quality management questions radical transparency radioligand therapy radiological imaging radiprodil ranibizumab rare disease ras Oncogene reSET (device) real-estate real-time real-time disclosure real-time monitoring real-time publishing real-world real-world evidence realistic medical scenarios reality rebranding reciprocal tariffs recombinational repair recurrence prevention redesable eye drop reduction in force reform refusal regulatory advocacy regulatory alignment regulatory barriers regulatory challenges regulatory changes regulatory complexity regulatory consulting regulatory decision regulatory decisions regulatory disclosure regulatory filing regulatory governance regulatory harmonization regulatory hurdle regulatory hurdles regulatory law regulatory meetings regulatory policy regulatory streamlining regulatory transparency reinstatement relapsed/refractory large-B-cell lymphoma relapsed/refractory multiple myeloma relatlimab renal response renewal reproductive health biotech reproxalap reputation rese-cel research collaboration research discontinuation research instrument development research partnerships research retraction research study research universities resignations resource shortage respiratory vaccines respiratory virus season restricted population restructuring charges revakinagene taroretcel-lwey revamp reverse merger review extension revumenib ribonucleoside-diphosphate reductase activity risk-based oversight risvodetinib romantasy ' roundtable royalty acquisition royalty management royalty monetization rubrics safety review safety signal salanersen sale rule salicylhydroxamic acid sample stabilization scPharmaceuticals scale-up scenario science-led storytelling scientific discovery scientist protest scrutiny second-line treatment secured secured debt securities fraud seladelpar self-administered drug self-administration self-collection devices self-injection business self-injection systems self-paying self-service semiconductor supply chains semiconductor tariffs sensor (device) serono setback seventh shortage shrinking budgets shutdown shutdowns site closures site transfer skin clearance small molecule agonists small molecule drugs small molecule inhibitors small molecule medicines small molecule therapy small-cell lung cancer solid-state batteries sonelokimab sotatercept-csrk sotorasib spatial proteomics spesolimab spin-out spinoff spotty complaint reporting staff exclusion staff reduction staff reorganization stake stake sale stance standards characteristics stealth stem cell-secreted proteins sterile cartridge facility sterile manufacturing steroid-sparing stock plunge stock price stock purchase stock repurchase programs stock sale stockholder stockpiling strain selection strategic alignment strategic collaborations strategic decision-making strategic investors strategic options strategic overhaul strategic partnership strategic pivot strategic reserves strategic transformation streamlined process streamlined review subcutaneous administration subcutaneous delivery subcutaneous formulation sublingual tablets submission delays submission program succession planning supercomputer supply chain exposure supply chain management supply chain resilience supply chains supply suspension suppurativa survival data survival rate suvorexant synovial fibroblasts synthetic construct synthetic royalty syphilis treatment tafamidis talazoparib taletrectinib target-effector pairs tariff avoidance tariff exemptions tariff increase tariff pause tariff threat tarlatamab-dlle team transformation tech partnerships technology innovation teen suicide tenofovir tenofovir disoproxil fumarate terminated - RoleStatus therapeutic areas therapeutic development therapeutic diversification therapeutic protein theta/beta ratio thrombotic disease thymus-targeted therapy ties time acceleration tissue models tividenofusp top-selling drugs topical amitriptyline topical treatment topline total health trade agreement trade compliance trade deficit trade deficits trade policy trans-splicing ribozyme transatlantic trade transdermal cannabidiol gel trauma qualifier traveler treatment approval treatment discontinuations treatment failure treatment prediction treatment resistance treatment-resistant hypertension trial design triple agonist triple seronegative triple therapy trispecific antibody troriluzole tumor response tumor shrinkage tumor-specific antigens turbulence turnaround strategy type 2 inflammation type I uUTIs unanimous vote uniQure unicorn startup university lawsuit unmet unreliable upfront upfront cash upfront discounts upgrade upheaval urothelial cancer ursodiol utilization qualifier uveal melanoma uveitic macular edema vaccine advisors vaccine advisory panel vaccine alternatives vaccine approval vaccine framework vaccine injuries vaccine licensing vaccine misinformation vaccine panel vaccine pipeline vaccine programs vaccine sales vaccine skepticism vaccine trial valuation value maximization value-based pricing vascular intervention vector vectorized veligrotug vial stopper defects vidofludimus vilobelimab violation viral shedding viral suppression vision improvement vobra vorolanib vote voting vusolimogene oderparepvec warning letters waveLINE-003 wear time wearable biosensor web navigation webinar weight loss business weight loss data weight loss market weight loss medication weight loss therapy weight regain weight-loss wet age-related macular degeneration white glove delivery whole-virus wind-down operations winners workflow automation workforce termination world 's z-rostudirsen zelicapavir zetomipzomib zidesamtinib zimberelimab zopapogene imadenovec-drba Élancé

Show more Show less

Report Abuse

Powered by Blogger